Mechanisms of Vascular Complications in Prediabetes

Medical Clinics of North America

Volumn 95, Issue 2, 2011, Pages 309-325

  Milman, Sofiya ^a   Crandall, Jill P ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Mechanisms; Microvascular complications; Prediabetes

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; RESISTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CLOTTING; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DNA MODIFICATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EPIGENETICS; FIBRINOLYSIS; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

ADIPONECTIN; ADIPOSE TISSUE; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; ENDOTHELIUM, VASCULAR; GLUCOSE INTOLERANCE; HUMANS; INSULIN RESISTANCE; LEPTIN; OBESITY; OXIDATIVE STRESS; PREDIABETIC STATE;

EID: 79251564089     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2010.11.004     Document Type: Review

References (123)

1. Levitsky Y., Pencina M., D'Agostino R., et al. Impact of impaired fasting glucose on cardiovascular disease. J Am Coll Cardiol 2008, 51:264-270.
2. Coutinho M., Gerstein H.C., Wang Y., et al. The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22:233-240.
3. Liu J., Grundy S., Wang W., et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes and the metabolic syndrome. Am Heart J 2007, 153:552-558.
4. The Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
5. Patel A., MacMahon S., Chalmers J., et al. ADVANCE: intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. The ADVANCE Collaborative Group.
6. Holman R., Paul S.K., Bethel M.A., et al. UKPDS 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
7. The NAVIGATOR Study Group Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362:1463-1476.
8. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-494.
9. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
10. Abdul-Ghani M.A., Tripathy D., DeFronzo R. Contributions of beta cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006, 29:1130-1139.
11. Haffner S.M., Mykkanen L., Festa A., et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000, 101:975-980.
12. Pankow J.S., Kwan D.K., Duncan B.B., et al. Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance. The Atherosclerosis Risk in Communities study. Diabetes Care 2007, 30:325-331.
13. Brunner E.J., Shipley M.J., Witte D.R., et al. Relationship between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care 2006, 29:26-31.
14. Meigs J.B., Nathan D.M., D'Agostino R.B., et al. Fasting and post challenge glycemia and cardiovascular disease risk. Framingham Offspring Study. Diabetes Care 2002, 25:1845-1850.
15. Blake D.R., Meigs J.B., Muller D.C., et al. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors. Results from the Baltimore Longitudinal Study on Aging. Diabetes 2004, 53:2095-2100.
16. Barr E.L.M., Boyko E.J., Zimmet P.Z., et al. Continuous relationship between non-diabetic hyperglycemia and both cardiovascular disease and all cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) Study. Diabetologia 2009, 52:415-424.
17. DECODE Study Group Glucose tolerance and cardiovascular mortality. Arch Intern Med 2001, 161:397-404.
18. Tanne D., Koren-Morag N., Goldbourt U. Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attack. Stroke 2004, 35:2351-2355.
19. Selvin E., Steffes M.W., Zhu H., et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010, 362:800-811.
20. Haffner S., Stern M., Hazuda H., et al. Cardiovascular risk factors in confirmed prediabetic individuals. JAMA 1990, 263:2893-2898.
21. Hu F., Stampfer M., Haffner S., et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002, 25:1129-1134.
22. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms. Diabetes Care 2010, 33:442-449.
23. Qiao Q., Jousilahti P., Eriksson J., et al. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. Diabetes Care 2003, 26:2910-2914.
24. Rijkeljkhuizen J., Nijpels G., Heine R., et al. High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes. Diabetes Care 2007, 30:332-336.
25. Rutter M., Meigs J., Sullivan L., et al. Insulin resistance, the metabolic syndrome and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005, 54:3252-3257.
26. Dormandy J.A., Charbonnel B., Eckland D.J.A., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE study: a randomised controlled trial. Lancet 2005, 366:1279-1289.
27. The BARI 2D Study Group BARI-2D: a randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009, 360:2503-2515.
28. Home P., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open label trial. Lancet 2009, 373:2125-2135.
29. Bian K., Doursout M., Murad F. Vascular system: role of nitric oxide in cardiovascular diseases. J Clin Hypertens (Greenwich) 2008, 10:304-310.
30. Montagnani M., Golovchenko I., Kim I., et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 2002, 277:1794-1799.
31. Cusi K., Maezano K., Osman A., et al. Insulin resistance differentially affects the PI 3-kinase and MAP-kinase-mediated signaling in human muscle. J Clin Invest 2000, 105:311-320.
32. Rask-Madsen C., Li Q., Freund B., et al. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab 2010, 11:379-389.
33. Ferrannini E., Iozzo P. Is insulin resistance atherogenic?. Atheroscler Suppl 2006, 7:5-10.
34. Iozzo P., Chareonthaitawee P., Rimoldi O., et al. Mismatch between insulin-mediated glucose uptake and blood flow in the heart of patients with type II diabetes. Diabetologia 2002, 45:1404-1409.
35. Bonetti P., Lerman L., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003, 23:168-175.
36. Tripathy D., Mohanty P., Dhindsa S., et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003, 52:2882-2887.
37. Kim J., Montagnani M., Koh K.K., et al. Reciprocal relationships between insulin resistance and endothelial dysfunction. Circulation 2006, 113:1888-1904.
38. Fantuzzi G., Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol 2007, 27:996-1003.
39. Poirier P., Giles T., Bray G., et al. Obesity and cardiovascular disease: pathophysiology, evaluation and effect of weight loss. Circulation 2006, 113:898-918.
40. Mathieu P., Poirier P., Pibarot P., et al. Visceral obesity: the link among inflammation, hypertension and cardiovascular disease. Hypertension 2009, 53:577-584.
41. Okura T., Nakata Y., Yamabuki K., et al. Regional body composition changes exhibit opposing effects on coronary heart disease risk factors. Arterioscler Thromb Vasc Biol 2004, 24:923-929.
42. Ferreira I., Snijder M., Twisk J.W.R., et al. Central fat mass versus peripheral fat and lean mass: opposite associations with arterial stiffness?. J Clin Endocrinol Metab 2004, 89:2632-2639.
43. DeMichele M., Panico S., Ianuzzi A., et al. Association of obesity and central fat distribution with carotid artery wall thickening in middle-aged women. Stroke 2002, 33:2923-2928.
44. Kuk J.L., Katzmarzyk P.T., Nichaman M.Z., et al. Visceral fat is an independent predictor of all-cause mortality in men. Obesity (Silver Spring) 2006, 14:336-342.
45. Gabriely I., Ma X., Yan G.X., et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine mediated process?. Diabetes 2002, 51:2951-2958.
46. Brochu M., Tchernoff A., Turner A.N., et al. Is there a threshold of visceral fat loss that improves the metabolic profile in obese postmenopausal women?. Metabolism 2003, 52:599-604.
47. Klein S., Fontana L., Young V.L., et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004, 350:2549-2557.
48. Weisberg S.P., McCann D., Desai M., et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
49. Cancello R., Clement K. Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG 2006, 113:1141-1147.
50. Knudsen J., Payne G., Borbouse L., et al. Leptin and mechanisms of endothelial dysfunction and cardiovascular disease. Curr Hypertens Rep 2008, 10:434-439.
51. Fantuzzi G., Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 2000, 68:437-446.
52. Yang R., Barouch L.A. Leptin signaling and obesity: cardiovascular consequences. Circ Res 2007, 101:545-559.
53. Wannamethee S.G., Tchernova J., Whincup P., et al. Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis 2007, 191(2):418-426.
54. Wang P., Ba Z.F., Chaudry I.H. Administration of tumor necrosis factor alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol 1994, 266:H2535-H2541.
55. Choy J.C., Granville D.J., Hunt D.W., et al. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 2001, 33:1673-1690.
56. Mohamed-Ali V., Goodrick S., Rawesh A., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor alpha in vivo. J Clin Endocrinol Metab 1997, 82:4196-4200.
57. Devaraj S., Xu D.Y., Jialal I. C-reactive protein increases plasminogen activating inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003, 107:398-404.
58. Cheng K.K., Lam K.S., Wang Y., et al. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes 2007, 56:1387-1394.
59. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling though a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
60. Kumada M., Kihara S., Ouchi N., et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004, 109:2046-2049.
61. Ginsberg H., Zhang Y.L., Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring) 2006, 14:41S-49S.
62. Adiels M., Olofsson S., Taskinen M., et al. Overproduction of very low-density lipoproteins is the hallmark of dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:1225-1236.
63. Grant P.J. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007, 262:157-172.
64. Osende J., Badimon J., Fuster V., et al. Blood thrombogenicity in type 2 diabetes is associated with glycemic control. J Am Coll Cardiol 2001, 38:1307-1312.
65. Mansfield M., Heywood D.M., Grant P.J. Circulating levels of factor VII, fibrinogen and von Willebrand factor and features of insulin resistance in first degree relatives of patients with NIDDM. Circulation 1996, 94:2171-2176.
66. Festa A., Williams K., Tracy R., et al. Progression of plasminogen activator-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 2006, 113:1753-1759.
67. Mertens I., Verrijkens A., Michiels J.J., et al. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006, 30(8):1308-1314.
68. Sakkinen P., Wahl P., Cushman M., et al. Clustering of procoagulation, inflammation and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000, 152:897-907.
69. Meigs J., Mittleman M., Nathan D., et al. Hyperinsulinemia, hyperglycemia and impaired hemostasis: the Framingham Offspring Study. JAMA 2000, 283:221-228.
70. Mazzone T., Chair A., Plutzky J. Cardiovascular disease risk in type 2 diabetes: insights from mechanistic studies. Lancet 2008, 371:1800-1809.
71. Brownlee M. The pathobiology of diabetic complications: a unifying hypothesis. Diabetes 2005, 54:1615-1625.
72. Saydah S.H., Miret M., Sung J., et al. Postchallenge hyperglycemia and mortality in a national sample of US adults. Diabetes Care 2001, 24:1397-1402.
73. Hanfeld M., Kroehler C., Henkel E., et al. Post-challenge hyperglycemia relates more strongly than fasting hyperglycemia with carotid intima-media thickness: the RIAD Study. Diabet Med 2000, 17:835-840.
74. Crandall J.P., Shamoon H., Cohen H., et al. Post-challenge hyperglycemia in older adults is associated with increased cardiovascular risk. J Clin Endocrinol Metab 2009, 94:1595-1601.
75. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention; 2008.
76. Choi S.W., Bensie I., Ma S.W., et al. Acute hyperglycemia and oxidative stress: direct cause and effect?. Free Radic Biol Med 2008, 4:1217-1231.
77. Inoguchi T., Li P., Umeda F., et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000, 49:1939-1945.
78. Marfella R., Quagliaro L., Nappo F., et al. Acute hyperglycemia induces oxidative stress in healthy subjects. J Clin Invest 2001, 108:635-636.
79. Monnier L., Mas E., Ginet C., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
80. Williams S.B., Goldfine A.B., Timimi F.K., et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998, 97:1695-1701.
81. Johnstone M.T., Creager S.J., Scales K.M., et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993, 88:2510-2516.
82. Wascher T.C., Schmoelzer I., Wiegratz A., et al. Reduction in postchallenge hyperglycemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest 2005, 35:551-557.
83. Xiang G., Sun H., Zhao L., et al. The antioxidant alpha-lipoic acid improves endothelial dysfunction induced by acute hyperglycemia during OGTT in impaired glucose tolerance. Clin Endocrinol 2008, 68:716-723.
84. Kawano H., Motoyama T., Hirashima O., et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of the brachial artery. J Am Coll Cardiol 1999, 34:146-154.
85. Title L., Cummings P., Giddens K., et al. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. J Am Coll Cardiol 2000, 36:2185-2191.
86. Major-Pedersen A., Ihlemann N., Hermann T., et al. Effects of oral glucose load on endothelial function and on insulin and glucose fluctuations in healthy individuals. Exp Diabetes Res 2008, 672021.
87. Beckman J., Goldfine A., Gordon M., et al. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 2001, 103:1618-1623.
88. Neri S., Signorelli S.S., Torrisi B., et al. Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance and healthy controls. Clin Ther 2005, 27:1764-1773.
89. Esposito K., Nappo F., Marfella R., et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002, 106:2067-2072.
90. Leurs P., Stolk R., Hamulyak K., et al. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care 2002, 25:1340-1345.
91. Stegenga M., van der Crabben S., Levi M., et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 2006, 55:1807-1812.
92. Santilli F., Formoso G., Sbraccia P., et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost 2010, 8:828-837.
93. El-Osta A., Brassachio D., Yao D., et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008, 205:2409-2417.
94. Isomma B., Henricsson M., Almgren P., et al. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001, 44:1148-1154.
95. Plantinga L.C., Crews D.C., Coresh J., et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 2010, 5:673-682.
96. Tapp R.J., Zimmet P.Z., Harper C.A., et al. Diagnostic thresholds for diabetes: the association of retinopathy and albuminuria with glycaemia. Diabetes Res Clin Pract 2006, 73:315-321.
97. Jia W., Gao X., Pang C., et al. Prevalence and risk factors of albuminuria and chronic kidney disease in Chinese population with type 2 diabetes and impaired glucose regulation: Shanghai Diabetic Complications Study (SHDCS). Nephrol Dial Transplant 2009, 24:3724-3731.
98. Gerstein H.C., Mann J.F.E., Yi Q., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421-426.
99. Hemmelgarn B.R., Manns B.J., Lloyd A., et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010, 303:423-429.
100. Atkins R.C., Polkinghorne K.R., Briganti E.M., et al. Prevalence of albuminuria in Australia: the AusDiab Kidney Study. Kidney Int Suppl 2004, 92:S22-S24.
101. Okpechi I.G., Pascone M.D., Swanepoel C.R., et al. Microalbuminuria and the metabolic syndrome in non-diabetic black Africans. Diab Vasc Dis Res 2007, 4:365-367.
102. Wahba I.M., Mak R.H. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2007, 2(3):550-562.
103. Ix J.H., Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol 2010, 21:406-412.
104. Steinberg H.O., Tarshoby M., Monestel R., et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997, 100:1230-1239.
105. Wong T.Y., Barr E.L.M., Tapp R.J., et al. Retinopathy in persons with impaired glucose metabolism: the Australian Diabetes Obesity Lifestyle (AusDiab) Study. Am J Ophthalmol 2005, 140:1157-1159.
106. Diabetes Prevention Program Research Group The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the diabetes prevention program. Diabet Med 2007, 24:137-144.
107. Rajala U., Laakso M., Qiao Q., et al. Prevalence of retinopathy in people with diabetes, impaired glucose tolerance, and normal glucose tolerance. Diabetes Care 1998, 21:1664-1669.
108. Gabir M.M., Hanson R.L., Dabelea D., et al. Plasma glucose and prediction of microvascular disease and mortality. Diabetes Care 2000, 23:1113-1118.
109. Cugati S., Cikamatana L., Wang J.J., et al. Five year incidence and progression of vascular retinopathy in persons without diabetes: the blue mountain eye study. Eye 2006, 20:1239-1245.
110. Van Leiden H.A., Dekker J.M., Moll A.C., et al. Risk factors for incident retinopathy in a diabetic population, the Hoorn study. Arch Ophthalmol 2003, 121:245-251.
111. Wong T.Y., Duncan B.B., Hill Golden S., et al. Associations between the metabolic syndrome and retinal microvascular signs: the atherosclerosis risk in communities study. Invest Ophthalmol Vis Sci 2004, 45:2949-2954.
112. Wong T.Y., Mitchell P. Hypertensive retinopathy. N Engl J Med 2004, 351:2310-2317.
113. Ziegler D., Rathmann W., Dickhaus T., et al. Prevalence of polyneuropathy in prediabetes and diabetes is associated with abdominal obesity and macroangiopathy. Diabetes Care 2008, 31:464-469.
114. Singleton J.R., Smith A.G. Neuropathy associated with prediabetes: what is new in 2007?. Curr Diab Rep 2007, 6:420-424.
115. Singelton J.R., Smith A.G., Bromberg M.B. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001, 24:1448-1453.
116. Sumner C.J., Sheth S., Griffin J.W., et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003, 60:108-111.
117. Panzer C., Lauer M., Brieke A., et al. Association of fasting plasma glucose with heart recovery in healthy adults. Diabetes 2002, 51:803-807.
118. Putz Z., Tabak A.G., Toth N., et al. Noninvasive evaluation of neural impairment in subjects with impaired glucose tolerance. Diabetes Care 2009, 32:181-183.
119. Vincent A.M., Hinder L.M., Pop-Busui R., et al. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst 2009, 14:257-267.
120. Barr E.L., Wong T.Y., Tapp R.J., et al. Is peripheral neuropathy associated with retinopathy and albuminuria in individuals with impaired glucose metabolism?. Diabetes Care 2006, 29:1114-1116.
121. Green A.Q., Krishnan S., Finucane F.M., et al. Altered c-fiber function as an indicator of early peripheral neuropathy in individuals with impaired glucose tolerance. Diabetes Care 2010, 33:174-176.
122. Costa L.A., Canani L.H., Lisboa H.R., et al. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in type 2 diabetes. Diabet Med 2004, 21:252-255.
123. Pop-Busui R., Sima A., Stevens M. Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev 2006, 22:257-273.